TiGenix: Funding Received And Cx611 Safety Data Provides Good News
Edison | Dec 23, 2012 11:09PM ET
TiGenix (TIG.BR) has completed a private placement issuing 8.6m shares for €6.7m cash at €0.78/share. FY12 operational burn was in line with expectations but some alternative funding sources have not materialised (a subsidiary sale did not occur) or been delayed into 2013. The good news is Cx611 (cultured adipose stem cells) safety data has shown no problems. Safety is an important issue for any systemic allogeneic stem cell therapy. Dose and some efficacy data are due in Q213. An indication will be selected for further development if efficacy is seen.
Product and trial progress: Cx611 safe, full data in Q2
The Cx611 Phase IIa dose-escalating study in 53 rheumatoid arthritis patients is the most clinically advanced use of stem cells to control an autoimmune disease. The endpoints are safety, tolerability and efficacy. The safety endpoint has been achieved and data released. Only two patients (4%) had adverse events and only one discontinued the study. This could lead to a Phase IIb with a disease score endpoint. The unblinded dose and efficacy data will be released in Q213 (due April). In other trials, the Cx601 Phase III in Crohn’s perianal fistula tracts started in July. The Cx621 inguinal (groin) lymph-node injection safety study showed the method was safe.
Cash placement and financial revision
Edison has scaled back its FY12 Chondrocelect sales target from 180 to 170 implying about €3.7m revenue. The 2013 target has been revised down to 350 from 450. Middle East distribution is now in place and a major EU country should sign in H113 (but is not now in our forecasts). ChrondroCelect may be cash neutral in 2014 but TiGenix overall will see cash outflows to 2016 unless a deal on Cx601 is struck (potentially globally in 2013). The new manufacturing site is licensed and will be operational in 2013 with excess capacity planned to be leased out. FY12 cash burn is estimated at €1.2m per month: €14m. With the placement cash due 27 December, the year-end cash will be about €11m. The placement with other funding should take TiGenix though 2013 but a Cx601 deal will be required to reach 2014.
Valuation: Placing of 8.6m shares, funding into 2014
The January 2013 indicative value has been revised to €1.90 on a 15-fold multiple due to lower immediate revenue expectations, more shares in issue and with a push back to 2016 for overall cash neutrality. Note: this excludes any deal value on Cx601 but this may be substantial. A low 1,000 maximum ChrodroCelect scenario indicates €1.55/share implying significant upside from the placing price of €0.78.
Get The News You Want
To Read the Entire Report Please Click on the pdf File Below.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.